Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 29, Issue 3, 2013, Pages 246-249

  Nascimento, Areana Diogo ^a   Lara, Lucia Alves Silva ^a   De Sá Rosa E Silva, Ana Carolina Japur ^a   Ferriani, Rui Alberto ^a   Reis, Rosana Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti mullerian hormone; Hyperandrogenism; Insulin resistance; PCOS

Indexed keywords

ANDROGEN; GLUCOSE; GONADOTROPIN; HORMONE; HYDROXYPROGESTERONE; INSULIN; METFORMIN; MUELLERIAN INHIBITING FACTOR; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLICULAR PHASE; GLUCOSE BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LONGITUDINAL STUDY; METABOLIC PARAMETERS; OPEN STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

17-ALPHA-HYDROXYPROGESTERONE; ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; FEMALE; FOLLICULAR PHASE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LONGITUDINAL STUDIES; LUTEINIZING HORMONE; METFORMIN; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; TESTOSTERONE; UP-REGULATION; YOUNG ADULT;

EID: 84874313184     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.736563     Document Type: Article

References (27)

1. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107-117. (Pubitemid 38519332)
2. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28-38.e25.
3. de Paula Martins W, Santana LF, Nastri CO, Ferriani FA, de Sa MF, Dos Reis RM. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. Eur J Obstet Gynecol Reprod Biol 2007;133:203-207. (Pubitemid 47069683)
4. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579. (Pubitemid 126537875)
5. Dominguez LJ, Davidoff AJ, Srinivas PR, Standley PR, Walsh MF, Sowers Jr. Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology 1996;137:113-121. (Pubitemid 26004981)
6. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894-1901. (Pubitemid 36645188)
7. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352: 1223-1236.
8. Santana LF, de Sá MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol 2004;19:88-96. (Pubitemid 39331409)
9. Eldar-Geva T, Margalioth EJ, Gal M, Ben-Chetrit A, Algur N, Zylber-Haran E, Brooks B, et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005;20:1814-1819. (Pubitemid 40932361)
10. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007;14:602-610.
11. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006;21:3103-3107. (Pubitemid 44811610)
12. Chu MC, Carmina E, Wang J, Lobo RA. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B. Fertil Steril 2005;84:1685-1688. (Pubitemid 41785664)
13. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002;77:141-146. (Pubitemid 34093906)
14. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: Relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957-5962. (Pubitemid 38033078)
15. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
16. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661-665. (Pubitemid 39243189)
17. Catteau-Jonard S, Pigny P, Reyss AC, Decanter C, Poncelet E, Dewailly D. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:4138-4143. (Pubitemid 350074723)
18. Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005;83:130-136. (Pubitemid 40094791)
19. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008;14:367-378. (Pubitemid 351858976)
20. Franks S, Hardy K. Aberrant follicle development and anovulation in polycystic ovary syndrome. Ann Endocrinol (Paris) 2010;71:228-230.
21. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008;93:82-90.
22. Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a 6-month study. J Clin Endocrinol Metab 2005;90:6072-6076. (Pubitemid 41606527)
23. Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005;21:154-160. (Pubitemid 41597556)
24. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053.
25. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: Results of a retrospective cohort study. Curr Med Res Opin 2004;20:565-572. (Pubitemid 38525165)
26. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 2007;87:870-875. (Pubitemid 46550403)
27. Tomova A, Deepinder F, Robeva R, Kirilov G, Mechandjiev Z, Kumanov P. Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm Metab Res 2011;43:723-727.